newsfilter
← Latest News
GlobeNewswire·

Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

  • Turn Therapeutics Inc. (NASDAQ: TTRX) began trading on October 8, 2025, after completing its direct listing.
  • The company entered a global supply, development, & license agreement with Medline to commercialize products using its PermaFusion® platform.
  • Arthur Golden & Dr. Kent Kester were appointed to the Board of Directors to enhance regulatory, operational, & infectious disease expertise.
  • Andrew Scott joined as Vice President of Corporate Communications to oversee investor relations & capital markets strategy.
  • The company's Intranasal Vaccine Program demonstrated 14 days of ambient temperature stability & 28 days of refrigerated viability.
  • A clinical trial commenced for the first topical IL-36/IL-31 inhibitor intended for eczema treatment.
  • R&D expenses for Q3 2025 were $158,699, while G&A expenses rose to $1.75 million due to costs related to the Nasdaq listing.
  • The company reported a net loss of $1,904,184 for the quarter ended September 30, 2025.
  • As of September 30, 2025, Turn Therapeutics held $3.11 million in cash & cash equivalents.